Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer.

Aditya BardiaAyca GucalpNoashir DaCostaNashat GabrailMichael DansoHaythem AliKimberly L BlackwellLisa A CareyJoel R EisnerEdwina S Baskin-BeyTiffany A Traina

Published in: Breast cancer research and treatment (2018)

Once-daily seviteronel was generally well tolerated in women with and 450 mg QD was chosen as the RP2D.

Keyphrases

estrogen receptor
open label
physical activity
double blind
placebo controlled
study protocol